1. Home
  2. IMAB vs MNOV Comparison

IMAB vs MNOV Comparison

Compare IMAB & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMAB
  • MNOV
  • Stock Information
  • Founded
  • IMAB 2014
  • MNOV 2000
  • Country
  • IMAB United States
  • MNOV United States
  • Employees
  • IMAB N/A
  • MNOV N/A
  • Industry
  • IMAB Biotechnology: Pharmaceutical Preparations
  • MNOV Biotechnology: Pharmaceutical Preparations
  • Sector
  • IMAB Health Care
  • MNOV Health Care
  • Exchange
  • IMAB Nasdaq
  • MNOV Nasdaq
  • Market Cap
  • IMAB 79.9M
  • MNOV 91.7M
  • IPO Year
  • IMAB 2020
  • MNOV 2005
  • Fundamental
  • Price
  • IMAB $0.95
  • MNOV $1.87
  • Analyst Decision
  • IMAB Strong Buy
  • MNOV Strong Buy
  • Analyst Count
  • IMAB 3
  • MNOV 1
  • Target Price
  • IMAB $8.00
  • MNOV $9.00
  • AVG Volume (30 Days)
  • IMAB 289.3K
  • MNOV 17.9K
  • Earning Date
  • IMAB 03-13-2025
  • MNOV 02-18-2025
  • Dividend Yield
  • IMAB N/A
  • MNOV N/A
  • EPS Growth
  • IMAB N/A
  • MNOV N/A
  • EPS
  • IMAB N/A
  • MNOV N/A
  • Revenue
  • IMAB $3,313,984.00
  • MNOV N/A
  • Revenue This Year
  • IMAB N/A
  • MNOV N/A
  • Revenue Next Year
  • IMAB N/A
  • MNOV N/A
  • P/E Ratio
  • IMAB N/A
  • MNOV N/A
  • Revenue Growth
  • IMAB N/A
  • MNOV N/A
  • 52 Week Low
  • IMAB $0.84
  • MNOV $1.12
  • 52 Week High
  • IMAB $2.00
  • MNOV $2.55
  • Technical
  • Relative Strength Index (RSI)
  • IMAB 43.17
  • MNOV 42.84
  • Support Level
  • IMAB $0.95
  • MNOV $1.82
  • Resistance Level
  • IMAB $1.04
  • MNOV $1.97
  • Average True Range (ATR)
  • IMAB 0.06
  • MNOV 0.07
  • MACD
  • IMAB -0.01
  • MNOV -0.00
  • Stochastic Oscillator
  • IMAB 10.53
  • MNOV 20.83

About IMAB I-MAB

I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).

About MNOV Medicinova Inc

MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.

Share on Social Networks: